Medicare Enrolled
Dr. Joseph Oommen, MD
Neurology · Beaumont, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Oommen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Oommen? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Oommen
Dr. Joseph Oommen is a neurology in Beaumont, TX, with 19 years in practice. Based on federal Medicare data, Dr. Oommen performed 3,494 Medicare services across 2,142 unique beneficiaries.
Between the years covered by Open Payments, Dr. Oommen received a total of $9,215 from 69 pharmaceutical and/or device companies across 531 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Oommen is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 15% volume in TX$ $9,215 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,494
Medicare services
Top 15% in TX for neurology
2,142
Unique beneficiaries
$105
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~184 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient, complex (40-54 min) | 695 | $131 | $330 |
| Injection, thiamine hcl, 100 mg | 417 | $2 | $89 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 386 | $202 | $515 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 374 | $1 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 217 | $47 | $186 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 128 | $10 | $28 |
| Measurement of brain wave activity (eeg), awake and drowsy | 97 | $285 | $728 |
| Evaluation of neuropsychological test, first hour | 96 | $101 | $252 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 96 | $25 | $65 |
| Evaluation of brain response to sound for determination of hearing threshold with interpretation and report | 95 | $88 | $214 |
| Measurement of nerve conduction using visual stimulation testing with report | 95 | $50 | $126 |
| Measurement of brain wave activity (eeg), digital analysis | 95 | $210 | $514 |
| Extended office or other outpatient service by clinical staff, first hour | 83 | $13 | $56 |
| New patient office visit, complex (60-74 min) | 80 | $159 | $410 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 78 | $72 | $179 |
| EEG, extended monitoring | 66 | $324 | $820 |
| Complete ultrasound of within the brain blood flow | 58 | $195 | $517 |
| Ultrasound of both sides of head and neck blood flow | 41 | $142 | $362 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with intermittent monitoring | 36 | $832 | $3,089 |
| Ultrasound study of arm and leg arteries | 33 | $62 | $154 |
| Testing of autonomic (sympathetic) nervous system function | 33 | $94 | $233 |
| Ultrasonic guidance for needle placement | 31 | $42 | $115 |
| Testing of autonomic nervous system function and heart rate response to deep breathing | 30 | $67 | $165 |
| Nerve conduction, 5-6 studies | 24 | $97 | $354 |
| Punch biopsy, each additional skin growth | 21 | $45 | $122 |
| Sleep study including heart rate, breathing, and sleep time | 14 | $111 | $290 |
| Nerve conduction, 11-12 studies | 14 | $173 | $476 |
| Office visit, established patient (30-39 min) | 14 | $99 | $245 |
| Echocardiogram, transthoracic | 12 | $150 | $373 |
| Measurement of brain wave activity (eeg), continuous | 12 | $208 | $854 |
| Office visit, established patient (20-29 min) | 12 | $64 | $164 |
| Punch biopsy, first skin growth | 11 | $92 | $250 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
17.3% high complexity
25.4% medium
57.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,215
Total received (2018-2024)
Avg $1,316/year across 7 years
Top 29% in TX for neurology
69
Companies
531
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,188 (99.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$27 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,056
2023$1,930
2022$1,674
2021$976
2020$388
2019$1,290
2018$1,900
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ACADIA Pharmaceuticals Inc
$1,109
ABBVIE INC.
$978
UCB, Inc.
$499
Novartis Pharmaceuticals Corporation
$472
PFIZER INC.
$407
Teva Pharmaceuticals USA, Inc.
$367
Biogen, Inc.
$343
EMD Serono, Inc.
$300
Neurelis, Inc.
$289
Lundbeck LLC
$285
GENZYME CORPORATION
$251
US WorldMeds, LLC
$214
Sunovion Pharmaceuticals Inc.
$195
Boston Scientific Corporation
$192
ARBOR PHARMACEUTICALS, INC.
$157
Eisai Inc.
$141
Supernus Pharmaceuticals, Inc.
$139
Assertio Therapeutics, Inc.
$134
Amneal Pharmaceuticals LLC
$126
E.R. Squibb & Sons, L.L.C.
$126
Grifols USA, LLC
$124
AbbVie Inc.
$114
ASSERTIO THERAPEUTICS, Inc.
$112
Celgene Corporation
$96
Alexion Pharmaceuticals, Inc.
$95
ARGENX US, INC.
$93
JAZZ PHARMACEUTICALS INC.
$93
Neurocrine Biosciences, Inc.
$93
Sumitomo Pharma America, Inc.
$92
EISAI INC.
$89
Allergan, Inc.
$87
Lilly USA, LLC
$85
TG THERAPEUTICS, INC.
$85
Boehringer Ingelheim Pharmaceuticals, Inc.
$85
Almatica Pharma LLC
$74
Jazz Pharmaceuticals Inc.
$69
GE HealthCare
$67
Biohaven Pharmaceuticals, Inc.
$61
GE HEALTHCARE
$61
Allergan Inc.
$56
Kyowa Kirin, Inc.
$47
Acorda Therapeutics, Inc
$45
Amgen Inc.
$44
Upsher-Smith Laboratories LLC
$42
Inspire Medical Systems, Inc.
$39
Impax Laboratories, Inc.
$35
Greenwich Biosciences, Inc.
$35
Biohaven Pharmaceutical Holding Company Ltd.
$33
CSL Behring
$33
Vertical Pharmaceuticals, LLC
$33
Puma Biotechnology, Inc.
$32
Corium, LLC
$29
Otsuka America Pharmaceutical, Inc.
$27
LivaNova USA, Inc.
$24
Abbott Laboratories
$24
PUMA BIOTECHNOLOGY, INC.
$23
Genentech USA, Inc.
$21
Takeda Pharmaceuticals U.S.A., Inc.
$21
SK Life Science, Inc.
$20
InSightec,Inc
$19
Marinus Pharmaceuticals, Inc.
$18
TESARO, Inc.
$18
BOSTON SCIENTIFIC CORPORATION
$17
Avion Pharmaceuticals
$16
IMPEL PHARMACEUTICALS INC.
$16
Avanir Pharmaceuticals, Inc.
$15
MITSUBISHI TANABE PHARMA AMERICA, INC.
$14
Exelixis Inc.
$12
AQUESTIVE THERAPEUTICS, INC.
$12
Top 3 companies account for 28.1% of total payments
Associated products mentioned in payments ›
ADUHELM · AIMOVIG · AJOVY · APOKYN · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Adlarity · Aimovig · Austedo XR · BOTOX · BRIUMVI · Briviact · COPAXONE · Cabometyx · Cambia · Dhivy · ELIQUIS · EMGALITY · EMPLICITI · EPIDIOLEX · Epidiolex · Exablate · Fintepla · Fycompa · GILOTRIF · GRALISE · Gamunex-C · General - DBS · Gralise · Halaven · Hizentra · Horizant · INBRIJA · INFINITY · INGREZZA · INSPIRE · KESIMPTA · KOSELUGO · KYNMOBI · LEMTRADA · LONHALA MAGNAIR · LORZONE · Lenvima · Leqembi · MAVENCLAD · MAYZENT · MYOBLOC · Mavenclad · NERLYNX · NINLARO · NORTHERA · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Nerlynx · Neupro · Nourianz · Nuedexta · OPDIVO · OSMOLEX ER · OXTELLAR XR · Ocrevus · Ongentys · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · RADICAVA · RYTARY · Rebif · SOLIRIS · SPINRAZA · SYMPAZAN · TECFIDERA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TROKENDI XR · TYSABRI · Trudhesa · UBRELVY · VALTOCO · VERCISE · VNS Therapy · VYEPTI · VYVGART · VYVGART HYTRULO · Vercise · Xadago · ZEJULA · ZEPOSIA · ZTALMY · Zipsor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $264 per 100 Medicare services performed
Geographic Context
Neurologys within 10 mi
10
Per 100K population
3.9
County median income
$59,934
Nearest hospital
CHRISTUS SOUTHEAST TEXAS- ST ELIZABETH
2.5 mi
2.5 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Oommen is a clinical cardiology specialist, with above-average Medicare volume (top 15% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Oommen experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Oommen performed 695 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Oommen receive payments from pharmaceutical companies?
Yes. Dr. Oommen received a total of $9,215 from 69 companies across 531 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Oommen's costs compare to other neurologys in Beaumont?
Dr. Oommen's average Medicare payment per service is $105. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Oommen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologys in Beaumont
Browse neurologys in Beaumont ranked by procedure volume and transparency data.
Highest volume
Top Neurologys in TX
Neurologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologys in TX
Which TX neurologys receive the most from drug and device companies.
By company
ACADIA Pharmaceuticals Inc Payments to Doctors
See all physicians who received payments from ACADIA Pharmaceuticals Inc.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC..
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology